Business
Patient Five Cancer-Free After Single PDT Treatment
Theralase Provides Update on 9 Months Post Treatment Cystoscopy Analysis TORONTO, ONTA...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Patient Five Cancer-Free After Single PDT TreatmentTheralase Provides Update on 9 Months Post Treatment Cystoscopy Analysis TORONTO, ONTARIO / ACCESSWIRE / November 8, 2018 / Theralase Technologies Inc. (\"Theralase®\" or the \"Company\")(TSXV: TLT) (OTCQB: TLTFF), a clinical stagepharmaceutical company dedicated to the research and development of lightactivated Photo Dynamic Compounds (\"PDCs\") and their associated drugformulations intended to safely andeffectively destroy various cancers has provided anupdate on patient five, enrolled and treated in the recently completed Phase IbNon-Muscle Invasive Bladder Cancer (\"NMIBC\")clinical study (\"Study\").The Study's purpose was to evaluate TLD-1433,Theralase's lead PDC, for the primary endpoint of safety and tolerability, witha secondary endpoint of pharmacokinetics (movement and exit of drug withintissue) and an exploratory endpoint of efficacy.Theralase'sAnti-Cancer Treatment involves the instillation of a water-based solution of Theralase'slead anti-cancer PDC, TLD-1433 at the Therapeutic Dose (0.70 mg/cm2), via a catheterinserted through the urethra into the bladder of the patient, to allow the PDCto be preferentially absorbed by NMIBC tumours. The bladder is then drained ofthe solution, flushed with sterile water to remove non-absorbed solution andrefilled with sterile water via a cystoscope. A fibre optic assembly, known asa Laser Emitter emits laser light toactivate TLD-1433, while a proprietary Dosimetry System detects the emitted laserlight, used for patient safety and efficacy. Both devices are inserted through thecystoscope, with the sole purpose of activating the absorbed PDC to destroy theNMIBC tumours.Thetreatment was well tolerated by the patient, who demonstrated no tumour recurrenceor presence of disease at the 90 day or 180 day clinical and cystoscopy assessment.Thepatient has met Study endpoints demonstratingachievement of the primary, secondary and exploratory endpoints at 90 and 180days and now at 270 days post treatment that marks a new achievement for theCompany.Arkady Mandel, M.D., Ph.D., D. Sc., Interim Chief Executive Officer andChief Scientific Officer of Theralase stated, \"This is an example of the enormous opportunity that awaits thisyoung Company in the treatment of cancer. For NMIBC, a Complete Response (\"CR\") is defined by the FDA as the d...